Tag Archives: Insulin Resistance

Early onset type 2 diabetes is no longer rare, and its rise among younger adults raises serious concerns. What happens when a chronic condition that typically appears later in life begins decades earlier? Much like starting a marathon with added weight, younger patients face a longer disease course and a …

Using GLP-1 therapy for lean type 2 diabetes challenges a long-standing assumption in diabetes care: that glucagon-like peptide-1 receptor agonists are primarily for patients with obesity. But what if body mass index is not the right guide for treatment decisions? Lean individuals with type 2 diabetes often exhibit insulin resistance, …

The link between metabolism and reproduction is gaining attention, especially as questions about GLP-1 therapy and male fertility begin to surface in clinical practice. For years, male fertility evaluations focused mainly on hormones and anatomy. However, what if the root problem starts with metabolic health? Obesity and insulin resistance are …

The conversation around GLP-1 therapies has shifted quickly. While most clinicians focus on weight loss and glucose lowering, new data on GLP-1 microbiome effects suggest something deeper may be happening in the gut. Could these medications reshape the intestinal ecosystem in ways that support long-term metabolic health? Increasingly, researchers believe …

GLP-1 receptor agonists are transforming diabetes and obesity care. However, as more women of reproductive age use medications like semaglutide, liraglutide, and tirzepatide, questions about how GLP-1 therapies affect fertility and pregnancy are becoming increasingly common. Can patients conceive safely while taking these agents? Do they improve ovulation in women …

For years, GLP-1 receptor agonists have been associated with older adults who already have type 2 diabetes or established cardiovascular disease. However, metabolic dysfunction does not suddenly appear at age 60. In fact, obesity, insulin resistance, and prediabetes often begin decades earlier. That is why conversations around GLP-1 therapy in …

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide. Traditionally, clinicians have associated MASLD with obesity, insulin resistance, and type 2 diabetes, often using body mass index (BMI) and A1C as screening triggers. However, an important shift is occurring …

Could a diabetes medication help women with PCOS regain control of their cycles and metabolism? GLP‑1 receptor agonists, best known for treating type 2 diabetes and obesity, are showing promise for women with polycystic ovary syndrome (PCOS). These medications may support weight loss, improve insulin resistance, and even lead to …

Could something as simple as a mineral or vitamin really shift the trajectory of type 2 diabetes? It’s a question both patients and clinicians increasingly ask as supplements gain popularity and more studies explore their potential benefits. While standard treatments remain foundational, micronutrients like magnesium and vitamin D have sparked …

Starting insulin early in the course of type 2 diabetes may seem counter‑intuitive. After all, many patients and clinicians treat insulin as a “last resort.” Yet what if early insulin initiation could actually change the trajectory of the disease — preserving pancreatic function, improving long‑term control, and reducing complications? In …